Morgan Hatfield, NP
Allergy & Immunology · N Charleston, SCNPI 1104396910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Sanofi at 25.8% of the total. 2025 is the largest year on record at $1,897, more than ten times the $19 reported in 2020. That places this record below the midpoint for allergy & immunology clinicians in SC, where the typical reported total is $7,297.
Across 292 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$1K
- GSK$730
- Regeneron Healthcare Solutions, Inc.$543
- Genentech USA, Inc.$515
- Amgen$398
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,57896%
- Education$2484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 58 | $1,761 |
| AstraZeneca | 67 | $1,363 |
| GSK | 32 | $730 |
| Regeneron Healthcare Solutions, Inc. | 17 | $543 |
| Genentech USA, Inc. | 22 | $515 |
| Amgen | 24 | $398 |
| Novartis | 16 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $279 |
| Biocryst US Sales Co., LLC | 6 | $131 |
| Pfizer | 6 | $116 |
| Grifols USA, LLC | 4 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Pharming Healthcare, Inc. | 3 | $54 |
| LEO Pharma Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $37 |
| CSL Behring | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Alk-abello, Inc | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $23 |
| Kaleo, Inc. | 1 | $22 |
| Kedrion Biopharma, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $22 |
| Optinose US, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| USWM, LLC | 1 | $17 |
| AbbVie | 1 | $17 |
| Organon | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
How this compares
$6,826 in reported general payments places this provider in the 45th percentile of 46 allergy & immunology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 17 | $75,132 |
| XolairOmalizumab | 15 | $51,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $46,193 |
| Spiriva RespimatTiotropium Bromide | 23 | $18,827 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,812 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,975 |
| Epinephrine | 21 | $3,677 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,640 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,270 |
| Ipratropium Bromide | 21 | $731 |
| Fluticasone Propionate | 41 | $695 |
| Azelastine Hcl | 29 | $608 |
| Montelukast Sodium | 41 | $391 |
| Triamcinolone Acetonide | 12 | $199 |
| Hydrocortisone | 13 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $730 | $56,64477 claims |
| Boehringer IngelheimSpiriva Respimat | $37 | $18,82723 claims |
| AstraZenecaSymbicort | $1,363 | $6,97522 claims |
| Hikma Pharmaceuticals USAEpinephrine | $34 | $3,67721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 46 allergy & immunology providers in South Carolina.
Other allergy & immunology in N Charleston
- Thomas MurphyCharleston$653K
- Douglas JohnstonGreenville$329K
- Allen KaplanNorth Charleston$220K
- David AmrolColumbia$172K
- Ned RuppNorth Charleston$154K
- John RameyNorth Charleston$126K
- Jaime LagosSpartanburg$54K
- Patricia GerberNorth Charleston$17K
- Robin GoSpartanburg$14K
- Hector RodriguezWest Columbia$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.